Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of April 2026, with a specific announcement date of April 8, 2026. The filing details a significant corporate action: the transition from trading American Depositary Shares (ADSs) to a direct listing of ordinary shares on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the mechanics of the share exchange and listing transition rather than financial performance.
Material Changes
- Share Structure Transition: All outstanding ADSs will be mandatorily exchanged for ordinary shares on a one-to-one basis.
- Listing Change: Ordinary shares will commence trading on The Nasdaq Global Select Market under the existing ticker symbol "ASND" on April 20, 2026 (the "Effective Date").
- Trading Cessation: The last day of trading for ADSs on Nasdaq is expected to be April 17, 2026.
- Implementation Mechanism: The Bank of New York Mellon, as Depositary, will call for the surrender of ADSs. Holders through brokers or DTC will have ADSs automatically canceled and replaced with ordinary shares.
Outlook, Risks, and Management Commentary
Management anticipates the direct listing to be effective at the opening of trading on April 20, 2026. The filing includes extensive forward-looking statements regarding the timing and implementation of the exchange. Key risks identified include:
- Failure to complete the exchange on the anticipated timeline or at all.
- Eligibility issues for ordinary shares within the DTC system.
- Potential delays or conditions regarding Nasdaq listing approval.
- Different trading dynamics or reduced liquidity compared to ADS trading.
- Potential adverse tax consequences for ADS holders.
- Impact on other outstanding securities.
Investor Verification Checklist
- Confirm the final Effective Date of the direct listing (anticipated April 20, 2026).
- Verify the one-to-one exchange ratio between ADSs and ordinary shares.
- Check with your broker regarding the automatic conversion process and any potential tax implications.
- Monitor the last trading day for ADSs (anticipated April 17, 2026) to avoid trading on the wrong instrument.
- Review the Annual Report on Form 20-F filed on February 11, 2026, for broader business risks not detailed in this specific filing.